Actually, MET amplification is a relevant resistance mechanism to first-generation EGFR-TKIs, being detectable in approximately 5%-22% of NSCLC patients with acquired resistance to these drugs [26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.